RONAK
About US/Products/Reproductive Health & Fertility/Menotron®

Menotron®

Patient Details

Menotron®

Generic name: Menotropins
Dosage form: Lyophilized powder containing purified menotropins equivalent to 75 IU of human follicle-stimulating hormone (FSH) and 75 IU of human luteinizing hormone (LH) for preparation of injectable solution
Drug class: Gonadotropin
Indications: This medication is used to stimulate the growth of ovarian follicles in women undergoing assisted reproductive techniques, and to stimulate spermatogenesis in men, together with hCG administration.

Description

Menotron® (Menotropins) is a human gonadotropin extracted from the urine of postmenopausal women.
It promotes the growth and maturation of ovarian follicles in women who do not have primary ovarian failure and, in men, when combined with hCG, stimulates sperm production.

Indications for Use

  • Development of multiple ovarian follicles during assisted reproductive technology (ART) in women without primary ovarian failure.
  • Stimulation of spermatogenesis in men.

Dosage Form

Lyophilized powder containing 75 IU of follicle-stimulating hormone (FSH) and 75 IU of luteinizing hormone (LH) for preparation of injectable solution.

Preparation Instructions

  1. Wash and dry your hands thoroughly with soap and water.
  2. Remove the plastic caps from one vial of medication and one vial of solvent, and clean both rubber stoppers with an alcohol pad.
  3. Using a 2 mL syringe, withdraw 1 mL of solvent from the vial with the white cap.
  4. Inject the solvent into the vial containing the powder (green cap).
  5. Without removing the syringe, gently swirl the vial until a clear, particle-free solution is obtained (do not shake vigorously). Then withdraw the entire solution back into the syringe.

Dosage and Administration

  • Menotron® must be administered immediately after reconstitution.
    Patients requiring multiple vials per injection may dissolve up to six vials of Menotron® powder in 1 mL of solvent.
  • The drug may be administered intramuscularly or subcutaneously, depending on the indication.
  • For subcutaneous injections, the area around the navel (at least 3 cm away) is recommended. Rotate injection sites daily to avoid local irritation. Do not inject into painful, bruised, or red skin.
  • In both subcutaneous and intramuscular injections, the needle should be inserted at a 90° angle. Intramuscular injections are deeper than subcutaneous ones. Rapid needle insertion reduces discomfort.
  • If blood appears when pulling back the plunger during intramuscular injection, withdraw the needle and press the site with an alcohol pad.
  • After injection, gently massage the site to reduce pain and aid absorption.
    Note: Each syringe, vial of Menotron® powder, and vial of solvent are for single use only. Dispose of properly after use.

Missed Dose

If a dose is missed, consult your physician immediately.

Overdose

If more than the recommended dose is administered, inform your doctor or visit a medical center immediately.

Monitoring Requirements

  • Serum estradiol level monitoring.
  • Ultrasound to assess follicle growth and development.
    Because the evaluation of follicular development and ovulation depends on the physician’s judgment, no specific test can be universally recommended.

Contraindications

  • Pregnancy
  • Hypersensitivity to menotropin
  • Uncontrolled adrenal or thyroid disorders
  • Intracranial lesions (e.g., pituitary tumor)
  • Enlarged ovaries or ovarian cysts (except in polycystic ovary syndrome)
  • Infertility not related to ovulatory dysfunction
  • Elevated FSH levels indicating primary ovarian failure

Warnings and Precautions

  • Menotropins should only be prescribed by specialists in infertility disorders.
  • Ovarian hyperstimulation syndrome (OHSS) may occur during or after treatment. This condition can range from mild to severe and may develop after treatment discontinuation, peaking 7–10 days later. If severe OHSS occurs, treatment should be stopped, and hospitalization may be necessary.

Use During Pregnancy and Lactation

  • Menotropins is contraindicated during pregnancy.
  • It is not known whether menotropin is excreted in breast milk. Because of potential serious adverse effects in the infant, the physician should decide whether to discontinue the drug or stop breastfeeding.

Adverse Reactions

Like all medicines, Menotron® may cause side effects, though not everyone experiences them:

  • Abdominal pain, cramps, bloating, or swelling
  • Pain, inflammation, or redness at injection site
  • Ovarian Hyperstimulation Syndrome (OHSS)
  • Ectopic pregnancy
  • Congenital abnormalities in infants
  • Multiple pregnancies
  • Vascular or pulmonary complications

Drug Interactions

Consult your doctor or pharmacist before taking Menotropins with other medications or supplements.

Packaging

Each box contains four vials of lyophilized Menotron® powder and four vials of solvent (sodium chloride).

Storage Conditions

  • Keep out of sight and reach of children.
  • Store below 25°C, away from light and humidity.
  • Do not use beyond the expiry date indicated on the package.
  • Keep in original packaging until use.

References

  1. Menotropins: Drug Information, UpToDate 2025

  2. www.medicines.org.uk/emc/product/1294/smpc

Menotron®
Prescribing Information